Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Navidea Biopharmaceuticals's interest expense for the
three
months ended in Sep. 2023 was $ -0.10 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.61 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Navidea Biopharmaceuticals's Operating Income for the
three
months ended in Sep. 2023 was $ -2.13 Mil. Navidea Biopharmaceuticals's Interest Expense for the
three
months ended in Sep. 2023 was $ -0.10 Mil.
Navidea Biopharmaceuticals did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Navidea Biopharmaceuticals Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.61 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Navidea Biopharmaceuticals (OTCPK:NAVB) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Navidea Biopharmaceuticals's Interest Expense for the
three
months ended in Sep. 2023 was $-0.10 Mil. Its
Operating Income
for the
three
months ended in Sep. 2023 was $-2.13 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Sep. 2023 was $0.00 Mil.
Navidea Biopharmaceuticals's Interest Coverage for the quarter that ended in Sep. 2023 is calculated as
| Navidea Biopharmaceuticals did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Navidea Biopharmaceuticals (Navidea Biopharmaceuticals) Business Description
Traded in Other Exchanges
N/A
Address
4995 Bradenton Avenue, Suite 240, Dublin, OH, USA, 43017-3552
Navidea Biopharmaceuticals Inc is a biotechnology company specializied in precision medicine. Its products, precision immunodiagnostic agents and immunotherapeutic products are designed to assist in the identification of undetected diseases and to improve targeted treatment. The company's platform, known as Manocept technology, aims to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases. One of the company's products is Lymphoseek, a radioactive diagnostic agent indicated to locate lymph nodes.
Executives
| Craig Dais |
officer: Chief Financial Officer |
4995 BRADENTON AVENUE, SUITE 240, DUBLILN OH 43017 |
| Dana J Moss |
director |
4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017 |
| Jill Stefanelli |
director |
4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017 |
| Josh M Wilson |
director |
4795 BRADENTON AVE, STE 240, DUBLIN OH 43017 |
| Scott John K Jr. |
director, 10 percent owner |
30 BLUE HERON DR., GREENWOOD VILLAGE CO 80121 |
| Agnieszka Winkler |
director |
C/O INTER-TEL, INCORPORATED, 1615 SOUTH 52ND STREET, TEMPE AZ 85281 |
| Thomas F Farb |
director |
C/O SUMMIT PARTNERS, 222 BERKELEY ST 18TH FL, BOSTON MA 02116 |
| Michel Mikhail |
officer: Chief Regulatory Officer |
4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017 |
| Malcolm G Witter |
director |
4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017 |
| Alexander L Cappello |
director |
C/O THE CHEESECAKE FACTORY INC, 26901 MALIBU HILLS ROAD, CALABASAS HILLS CA 91301 |
| Amit Bhalla |
director |
4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017 |
| Joel H. Kaufman |
officer: Chief Business Officer |
4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017 |
| Jed Latkin |
officer: Interim COO |
152 W. 57TH STREET, 4TH FLOOR, NEW YORK NY 10019 |
| Sarah Kathryn Rouan |
director |
4995 BRADENTON AVENUE, SUITE 240, DUBLIN OH 43017 |
| Claudine Bruck |
director |
4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017-3552 |
Navidea Biopharmaceuticals (Navidea Biopharmaceuticals) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NAVB has been successfully added to your 